AAPL   322.94 (-0.12%)
FB   229.14 (-1.54%)
GOOGL   1,433.10 (-0.64%)
AMZN   2,465.07 (-0.30%)
NVDA   348.70 (-1.22%)
BABA   215.15 (+0.38%)
MU   48.07 (+2.67%)
GE   7.22 (+2.41%)
TSLA   884.51 (+0.33%)
AMD   52.50 (-1.94%)
ACB   14.37 (-1.10%)
GILD   74.18 (+1.26%)
DIS   121.69 (+2.48%)
NFLX   419.21 (-1.90%)
BAC   25.96 (+4.51%)
AAPL   322.94 (-0.12%)
FB   229.14 (-1.54%)
GOOGL   1,433.10 (-0.64%)
AMZN   2,465.07 (-0.30%)
NVDA   348.70 (-1.22%)
BABA   215.15 (+0.38%)
MU   48.07 (+2.67%)
GE   7.22 (+2.41%)
TSLA   884.51 (+0.33%)
AMD   52.50 (-1.94%)
ACB   14.37 (-1.10%)
GILD   74.18 (+1.26%)
DIS   121.69 (+2.48%)
NFLX   419.21 (-1.90%)
BAC   25.96 (+4.51%)
AAPL   322.94 (-0.12%)
FB   229.14 (-1.54%)
GOOGL   1,433.10 (-0.64%)
AMZN   2,465.07 (-0.30%)
NVDA   348.70 (-1.22%)
BABA   215.15 (+0.38%)
MU   48.07 (+2.67%)
GE   7.22 (+2.41%)
TSLA   884.51 (+0.33%)
AMD   52.50 (-1.94%)
ACB   14.37 (-1.10%)
GILD   74.18 (+1.26%)
DIS   121.69 (+2.48%)
NFLX   419.21 (-1.90%)
BAC   25.96 (+4.51%)
AAPL   322.94 (-0.12%)
FB   229.14 (-1.54%)
GOOGL   1,433.10 (-0.64%)
AMZN   2,465.07 (-0.30%)
NVDA   348.70 (-1.22%)
BABA   215.15 (+0.38%)
MU   48.07 (+2.67%)
GE   7.22 (+2.41%)
TSLA   884.51 (+0.33%)
AMD   52.50 (-1.94%)
ACB   14.37 (-1.10%)
GILD   74.18 (+1.26%)
DIS   121.69 (+2.48%)
NFLX   419.21 (-1.90%)
BAC   25.96 (+4.51%)
Log in

NASDAQ:ARNAArena Pharmaceuticals Stock Price, Forecast & News

$67.80
-0.42 (-0.62 %)
(As of 06/3/2020 12:40 PM ET)
Add
Compare
Today's Range
$66.85
Now: $67.80
$69.74
50-Day Range
$47.06
MA: $51.68
$59.77
52-Week Range
$32.95
Now: $67.80
$68.40
Volume24,906 shs
Average Volume907,886 shs
Market Capitalization$3.41 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.39
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment of decompensated heart failure. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Axovant Sciences GmbH; Outpost Medicine LLC; CY Biotech Company Limited; Boehringer Ingelheim International GmbH; Eisai Co., Ltd.; and Eisai Inc. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.
Read More
Arena Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$806.43 million
Cash Flow$9.11 per share
Book Value$21.38 per share

Profitability

Net Income$397.55 million
Net Margins-5,727.22%

Miscellaneous

Employees194
Market Cap$3.41 billion
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

How has Arena Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Arena Pharmaceuticals' stock was trading at $40.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARNA shares have increased by 70.6% and is now trading at $68.9650. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Arena Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 1 sell rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Arena Pharmaceuticals.

When is Arena Pharmaceuticals' next earnings date?

Arena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Arena Pharmaceuticals.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($2.00) earnings per share for the quarter, beating analysts' consensus estimates of ($2.28) by $0.28. The biopharmaceutical company earned $0.26 million during the quarter, compared to the consensus estimate of $1.58 million. Arena Pharmaceuticals had a negative net margin of 5,727.22% and a negative return on equity of 29.30%. Arena Pharmaceuticals's revenue for the quarter was down 100.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $12.10 EPS. View Arena Pharmaceuticals' earnings history.

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Shares of Arena Pharmaceuticals reverse split on the morning of Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for ARNA?

9 brokers have issued 1-year price objectives for Arena Pharmaceuticals' shares. Their forecasts range from $56.00 to $95.00. On average, they expect Arena Pharmaceuticals' share price to reach $72.38 in the next year. This suggests a possible upside of 4.9% from the stock's current price. View analysts' price targets for Arena Pharmaceuticals.

Has Arena Pharmaceuticals been receiving favorable news coverage?

Media coverage about ARNA stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arena Pharmaceuticals earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term. View the latest news aboutArena Pharmaceuticals.

Who are some of Arena Pharmaceuticals' key competitors?

What other stocks do shareholders of Arena Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arena Pharmaceuticals investors own include Advanced Micro Devices (AMD), Cytokinetics (CYTK), Canopy Growth (CGC), Inovio Pharmaceuticals (INO), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH) and Amarin (AMRN).

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the following people:
  • Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
  • Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
  • Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)
  • Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50)

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

Who are Arena Pharmaceuticals' major shareholders?

Arena Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (10.14%), Wellington Management Group LLP (9.44%), State Street Corp (3.75%), Alliancebernstein L.P. (2.45%), Eagle Asset Management Inc. (1.88%) and Lord Abbett & CO. LLC (1.69%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Preston Klassen, Randall E Woods, Robert Lisicki, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View institutional ownership trends for Arena Pharmaceuticals.

Which major investors are selling Arena Pharmaceuticals stock?

ARNA stock was sold by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Perceptive Advisors LLC, APG Asset Management N.V., APG Asset Management N.V., Cormorant Asset Management LP, AXA, WINTON GROUP Ltd, and Morgan Stanley. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Amit Munshi, Jayson Donald Alexander Dallas, Kevin Robert Lind, Randall E Woods, Robert Lisicki, Steven W Spector, and Vincent Aurentz. View insider buying and selling activity for Arena Pharmaceuticals.

Which major investors are buying Arena Pharmaceuticals stock?

ARNA stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Bank of New York Mellon Corp, Asymmetry Capital Management L.P., Nuveen Asset Management LLC, Schroder Investment Management Group, BlackRock Inc., JPMorgan Chase & Co., and Invesco Ltd.. View insider buying and selling activity for Arena Pharmaceuticals.

How do I buy shares of Arena Pharmaceuticals?

Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of ARNA stock can currently be purchased for approximately $68.97.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $3.47 billion and generates $806.43 million in revenue each year. The biopharmaceutical company earns $397.55 million in net income (profit) each year or $7.69 on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.

What is Arena Pharmaceuticals' official website?

The official website for Arena Pharmaceuticals is www.arenapharm.com.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.